Growth Hormone's short-term, low-dose effect on endothelial progenitor cell mobilization assessed in healthy adults

Cardiovascular disease is a leading cause of morbidity and mortality, often linked to endothelial dysfunction and impaired vascular repair. Endothelial progenitor cells (EPCs) play a crucial role in maintaining vascular integrity and promoting angiogenesis, making their mobilization from bone marrow a potential therapeutic target. Strategies to enhance EPC mobilization could offer novel approaches for preventing or treating vascular damage. Growth hormone (GH) has known anabolic and regenerative properties, and its potential to influence stem cell populations, including EPCs, warrants investigation in the context of vascular health. Understanding GH's impact on EPCs could inform future regenerative medicine strategies.

This was a non-randomized, non-blinded clinical trial (NCT00397592) involving 18 healthy adults. The study aimed to assess the effect of short-term, low-dose Growth Hormone therapy on the mobilization of endothelial progenitor cells from the bone marrow. Participants received Growth Hormone for a specified duration, though the exact dose, route, and frequency are not detailed in the provided summary. The primary endpoint was the mobilization of endothelial progenitor cells. No specific control arm is mentioned, indicating a single-arm observational assessment of GH's effect.

The provided clinical trial summary (NCT00397592) does not include specific findings or quantitative results regarding the effect of Growth Hormone on endothelial progenitor cell mobilization. The study was completed in January 2007, with an actual enrollment of 18 participants. However, the abstract's scope is limited to the study's objective and design, without detailing any observed changes in EPC levels, statistical significance, or other outcome measures. Therefore, no specific percentages, p-values, or fold-changes can be reported from this summary.